{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T01:20:56Z","timestamp":1771032056345,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Methotrexate (MTX) is recommended as a first-line conventional synthetic disease-modifying antirheumatic drug (csDMARD) for treating rheumatoid arthritis (RA). This retrospective study sought to identify an add-on csDMARD treatment strategy for RA patients with MTX-inadequate response (IR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We collected the cases of RA patients treated with salazosulfapyridine (SASP) or iguratimod (IGU) as the additional csDMARD for MTX-IR during a 24-month follow-up. We performed propensity score matching to evaluate the retention rate, clinical efficacy, and safety profile (n = 54, each group).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The retention rates at 24 months were 38.5% (MTX+SASP group) and 67.8% (MTX+IGU group). At 3 and 6 months, the MTX+IGU group\u2019s 28 joint-disease activity score (DAS28) was significantly decreased versus the MTX+SASP group, and at 3 months the MTX+IGU group\u2019s good-responder percentage (22.9%) was significantly higher versus the MTX+SASP group\u2019s good-responder percentage (10.7%). Conversely, compared to the MTX+SASP group, the MTX+IGU group showed a greater reduction in the estimated glomerular filtration rate from baseline during follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IGU is a useful add-on csDMARD for RA patients with MTX-IR; its high retention rate and good clinical response make it a useful combination therapy for controlling RA disease activity. However, the renal function should be monitored during follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac060","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T13:45:04Z","timestamp":1655127904000},"page":"472-480","source":"Crossref","is-referenced-by-count":4,"title":["Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching"],"prefix":"10.1093","volume":"33","author":[{"given":"Yuji","family":"Nozaki","sequence":"first","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Oribe","sequence":"additional","affiliation":[{"name":"Oribe Rheumachika, Naika Clinic , Oita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Itami","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan"},{"name":"Matsubara Mayflower Hospital , Kato, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Funahashi","sequence":"additional","affiliation":[{"name":"Matsubara Mayflower Hospital , Kato, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Matsubara Mayflower Hospital , Kato, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kindai University School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"2023092217012361300_R1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/ard.2006.057133","article-title":"Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study","volume":"66","author":"Capell","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023092217012361300_R6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/ard.58.4.220","article-title":"Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components","volume":"58","author":"Dougados","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/rheumatology\/36.10.1082","article-title":"Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial","volume":"36","author":"Haagsma","year":"1997","journal-title":"Br J Rheumatol"},{"key":"2023092217012361300_R8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/14397595.2019.1572267","article-title":"Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis","volume":"30","author":"Nozaki","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023092217012361300_R10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14397595.2018.1486939","article-title":"The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab","volume":"29","author":"Ebina","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023092217012361300_R11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/s10165-012-0724-8","article-title":"Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2023092217012361300_R12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.2006.054205","article-title":"Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values","volume":"66","author":"Inoue","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R13","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2023092217012361300_R14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2023092217012361300_R15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023092217012361300_R16","article-title":"The effectiveness and retention rate of iguratimod in Japanese rheumatoid arthritis patients with\/without methotrexate in daily medical care","volume":"10","author":"Inoue","year":"2020","journal-title":"Life (Basel)"},{"key":"2023092217012361300_R17","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1080\/01621459.2020.1713792","article-title":"Regression models and multivariate life tables","volume":"116","author":"Prentice","year":"2021","journal-title":"J Am Stat Assoc"},{"key":"2023092217012361300_R18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0006-3223(02)01867-X","article-title":"Assessing and interpreting treatment effects in longitudinal clinical trials with missing data","volume":"53","author":"Mallinckrodt","year":"2003","journal-title":"Biol Psychiatry"},{"key":"2023092217012361300_R19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023092217012361300_R20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis of methotrexate in the treatment of rheumatoid arthritis. Molecular basis of pharmacokinetics and pharmacodynamics","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"2023092217012361300_R21","first-page":"787","article-title":"Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts","volume":"32","author":"Yoshida","year":"2005","journal-title":"J Rheumatol"},{"key":"2023092217012361300_R22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"A EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023092217012361300_R23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00003495-199550010-00009","article-title":"Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis","volume":"50","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"2023092217012361300_R24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"CSP 551 RACAT investigators. Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O\u2019Dell","year":"2013","journal-title":"N Engl J Med"},{"key":"2023092217012361300_R25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-2143(99)90186-5","article-title":"Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells","volume":"133","author":"Kawakami","year":"1999","journal-title":"J Lab Clin Med"},{"key":"2023092217012361300_R26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","article-title":"Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice","volume":"42","author":"Tanaka","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2023092217012361300_R27","first-page":"2591","article-title":"Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells","volume":"28","author":"Kohno","year":"2001","journal-title":"J Rheumatol"},{"key":"2023092217012361300_R28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/14397595.2015.1069475","article-title":"Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod","volume":"26","author":"Yoshioka","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2023092217012361300_R29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1254\/jjp.67.305","article-title":"T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts","volume":"67","author":"Tanaka","year":"1995","journal-title":"Jpn J Pharmacol"},{"key":"2023092217012361300_R30","article-title":"Iguratimod: novel molecular insights and a new csDMARD for rheumatoid arthritis, from Japan to the world","volume":"11","author":"Nozaki","year":"2021","journal-title":"Life (Basel)"},{"key":"2023092217012361300_R31","first-page":"145","article-title":"The influence of iguratimod on renal function","volume":"31","author":"Hasegawa","year":"2019","journal-title":"Clinical Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac060\/44386465\/roac060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/472\/51715064\/roac060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/472\/51715064\/roac060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T17:30:24Z","timestamp":1695403824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/3\/472\/6607574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,13]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac060","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,6,13]]}}}